Baorui Pharmaceuticals to become top shareholder in Taifu Biotech, marking a new era in Taiwan’s biotech sector
The acquisition involves Taifu Biotech issuing new shares to Baorui, which will exchange its shares in Baorui Biotech, focusing on large-molecule CDMO (Contract Development and Manufacturing Organization) technology, for an equivalent number of Taifu shares. This merger will significantly enhance Baorui's footprint in the biotech sector and solidify its standing as a leading player in the industry.